Background Patients with acute coronary syndrome (ACS) are recognized by guidelines as remaining at high risk for adverse outcomes. Evidence from contemporary, representative ACS populations in a clinical practice setting is necessary to identify subgroups and strategies for improving patient outcomes. We aimed to describe event rates and risk factors in an ACS population over prolonged follow-up for cardiovascular end points. Methods and Results We identified 239 234 patients in the Optum Research Database (57.2% men; mean [standard deviation] age, 69.2 [12.2] years) with evidence of an ACS hospitalization (index ACS) during January 1, 2005 through December 30, 2018. Subgroups were based on index ACS event (myocardial infarction/unstable angina and revascularization status) and the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention. The 5-year event rate for the primary end point representing nonfatal myocardial infarction, nonfatal ischemic stroke, and cardiovascular death was 33.4% (95% CI, 33.1%-33.7%; <0.001). The risk of experiencing the primary end point was ≈6-fold higher immediately after discharge (≈40.9% annualized risk) as compared with the period 1+ years after hospitalization (≈6.4% annualized risk). Among subgroups, the 5-year primary end point event rate was highest for myocardial infarction without revascularization and a Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention ≥4, at 47.9% (95% CI, 47.3%-48.4%; <0.001) and 56.7% (95% CI, 55.9%-57.4%; <0.001), respectively. Conclusions Patients with ACS remain at very high risk of experiencing recurrent cardiovascular events, particularly early after discharge, with identifiable subgroups at multifold higher risk of specific clinical end points.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238606 | PMC |
http://dx.doi.org/10.1161/JAHA.121.022198 | DOI Listing |
JAMA Ophthalmol
January 2025
Centre for Eye Research Ireland, Environmental and Sustainability Health Institute, Technological University Dublin, Dublin, Ireland.
Importance: Additional data are required regarding atropine treatment regimens for control of myopia progression.
Objective: To investigate the efficacy and safety of different atropine regimens for myopia in children.
Design, Setting, And Participants: This was a secondary analysis of the 3-year results of the 24-Month Myopia Outcome Study of Atropine in Children (MOSAIC) trial, called the MOSAIC2 trial.
Int Orthop
January 2025
CHU de Nantes, Nantes University, CHU Nantes, Clinique Chirurgicale Orthopédique et Traumatologique, 1 Place Alexis Ricordeau, 44000, Nantes, France.
Purpose: Proximal femur megaprostheses (PFMPs) are used to manage large bone defects in both non-oncological indications (NOI) and oncological indications (OI). However, little is known about the comparative risks of reoperation and functional outcomes between these groups. This study aimed to evaluate the cumulative incidences of reoperation and functional results of PFMPs between NOI and OI.
View Article and Find Full Text PDFJ Assist Reprod Genet
January 2025
APHP Centre, Faculty of Medicine, Université Paris Cité, 75014, Paris, France.
Purpose: To evaluate if morphology and morphokinetics of cleaved embryos affect prenatal and perinatal outcomes.
Methods: This retrospective cohort study included 734 single fresh embryo transfer (SET) from ICSI from January 2014 to December 2020 at the Dijon University Hospital. Using time-lapse technology, embryos were defined as TOP or non-TOP according to morphological/morphokinetic criteria.
Eur Heart J
December 2024
Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
Background And Aims: Current knowledge about upper extremity artery disease (UEAD) is scarce. This study aimed to evaluate the prevalence, treatment patterns, and short- and long-term outcomes of patients suffering from UEAD.
Methods: Retrospective health claims data of patients who were hospitalized with a primary diagnosis of UEAD between 2010 and 2017 were analysed.
Background: Neuroendocrine neoplasias grade 3 (NEN G3) are rare tumors with poor prognosis and no established second-line therapy. The role of immune checkpoint blockade in these aggressive tumors remains unclear.
Methods: The phase II AVENEC study evaluated the effect of avelumab (AVE, 10 mg/kg IV Q2W) in 60 patients with well-differentiated high-grade neuroendocrine tumors (NET G3, N=22) or poorly differentiated neuroendocrine carcinomas (NEC, N=38) progressing after ≥ one prior chemotherapy (excluding Merkel cell and small-cell lung cancer).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!